Cumberland Pharma (CPIX) Reports Q1 EPS of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results
May 10, 2016 4:05 PM EDTNASHVILLE, Tenn., May 10, 2016 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2016 financial results with Net Revenues of $7.7 million and Adjusted Earnings of $0.3 million or $0.02 per share.
As of March 31, 2016, the Company had just under $90 million in Total Assets including over $51 million in cash and marketable securities. Total Liabilities were approximately $14 million and Total Shareholder's Equity was just over $75 million. Cumberland also had approximately $43 million in tax net operating loss carryforwards, resulting from the... More
